Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
OwnerJens STECHL, Irene NOWOTNY +3inventors
InventorsJens STECHL, Irene NOWOTNY, Claudia PFEIFFER, Jean-Louis PINQUIER, Jerome MSIHID
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated with stenosis or/and obstruction located in the pancreatic duct system, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.
Claims21
A pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated with stenosis or/and obstruction located in the pancreatic duct system, or/and in the circumventing pancreatic tissue, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.
A pharmaceutical composition for use in a palliative treatment, said composition comprising at least one GLP-1 agonist, and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.
A pharmaceutical composition for use in the treatment of pain, said composition comprising at least one GLP-1 agonist, and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.
A method of treatment of a disease or condition associated with stenosis or/and obstruction in the pancreatic duct system, said method comprising administrating to a subject in need thereof a pharmaceutical composition comprising at least one GLP-1 agonist, and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance.
(canceled)
(canceled)
Dependencies are inferred from the claim text.